If you have significant smoking history, or had been exposed to long term pollution, cooking biomass, second hand cigarette smoke, you might be at risk from Chronic Obstructive Pulmonary Disease (COPD) such as Bronchitis and Emphysema.

Smoking history or second hand cigarette smoke exposure

Burning biomass such as wood or waste for cooking

Pollution from cars and industries

Likely you have severe symptoms like these.

Feeling breathless and tired after walking short distances

 

Still feel breathless despite optimum drug therapy

If you still feel breathless despite optimum standard medical therapy, ask your doctor if you are a suitable candidate for other treatment options such as LVRS or Pulmonx Endobronchial Valve (EBV) Therapy

 

Lung Volume Reduction Surgery (LVRS):

LVRS is a irreversible surgical procedure performed to remove diseased, emphysematous lung tissue. The surgery has been shown to help improve breathing ability, lung capacity and overall quality of life in selected patients.

The National Emphysema Treatment Trial (NETT)’s results confirm that LVRS is beneficial for patients who have predominant upper lobe disease and low exercise capacity, as compared with medical treatment. While effective for some patients, there are risks involved with lung reduction surgery, including:

– Air leakage (air leaks from the lung tissue)
– Pneumonia or infection
– Stroke
– Bleeding
– Heart attack
– Death (due to worsening of above complications)

 

Pulmonx Endobronchial Valve (EBV) Therapy:

Unlike lung volume reduction surgery (LVRS) which involves an open incision. Endobronchial Valve (EBV) Therapy is reversible and is a minimally invasive procedure that uses no cutting or stitches. It also has far less complications than LVRS and can be reversed if needed.

Is an endoscopic lung volume reduction therapy that has been proven to significantly improve lung function, exercise capacity and quality of life for emphysema patients across four randomized, controlled clinical trials and in 20,000 patients worldwide.

Endobronchial valves are tiny devices are implanted in the airways of the lungs and act as one-way valves. They block off diseased parts of the lung and allow healthier regions to expand and function more efficiently.

In combination with its diagnostic companion products, it uniquely offers a prospectively proven method for predicting responders. It is also designed to be removable, preserving future treatment options for patients.

The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves and now considers current evidence sufficient to support routine use. The change in NICE guidance is based on safety and efficacy data from multiple randomized clinical trials evaluating the Zephyr EBV, which has demonstrated clinical and quality of life benefits, and long-term safety for eligible patients.

Click > Website Pulmonx
Click > Facebook Pulmonx

Patient Benefits:

Patients treated with the Zephyr Valve compared to patients on medication alone were able to:

  • Return to activities that were previously limited
  • Feel less shortness of breath
  • Walk longer distances
  • Have more energy
  • Feel more confident leaving their home

 

Treatment Centres:

Dr. Jamalul Azizi Abdul Rahaman
Pulmonologist
Hospital Serdang
Head of Pulmonology (Respiratory) Department
Click > Profile Link

Dr. Jamalul Azizi Abdul Rahaman
Pulmonologist
CVS Kuala Lumpur
Click > Profile Link

Dr. Kho Sze Shyang
Pulmonologist
Department of Respiratory Medicine
Sarawak General Hospital
Click > Profile Link

Dr. Rosmadi Ismail
Pulmonologist
Sunway Medical Centre
Click > Profile Link

Dr. Tie Siew Teck
Pulmonologist
Head of Division of Respiraotry Medicine
Sarawak General Hospital
Click > Profile Link

 

If you wish to obtain more details, you can enter your contact details below:

Note that if you choose to enter your contact details here, you are agreeing to share your personal details with this administrator.

Disclaimer: By completing this form, you agree to indemnify this website administrator, its subsidiaries and/or his associates or affiliates against any and all damages or liabilities that may potentially occur as a result from any advice or correspondence provided hereof.